18F- FDG PET/CT joint assessment of early therapeutic response in rheumatoid arthritis patients treated with rituximab

EJNMMI Reports

Table 5 Concordance of metabolic, ultrasonographic and biological responses at week 16 versus clinical response at week 24, compared to baseline

	Visual PET	cSUV	CI	# US+	CST	CRP
Sensitivity	66.7	66.7	66.7	100.0	100.0	100.0
Specificity	90.9	72.7	72.7	54.6	54.6	54.6
PPV	66.7	40.0	40.0	37.5	37.5	37.5
NPV	90.9	88.9	88.9	100.0	100.0	100.0
Accuracy	85.7	71.4	71.4	64.3	64.3	64.3

Only sustained clinical responses were considered as a clinical responses; transient and absence of response were considered as a non-response. Visual PET: number of PET-positive joints; cSUV Cumulative SUV, CI Composite SUV index, # US+ Number of US-positive joints, CST Cumulative synovial thickness, CRP C-reactive protein. Results are given in %